Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

Table 2 Univariate and multivariable analysis of predictors of OS from the diagnosis of bone metastases (BMs) in patients with RCC

	*UVA* *			*MVA* **
	HR	*95% CI*	P	HR	*95% CI*	P
Age (<65 vs ≥65)	0.8	0.64-0.99	0.04	0.83	0.65-1.07	0.15
Gender (M vs F)	0.84	0.68-1.04	0.31
Histology (CC vs NCC)	1.45	1.08-1.95	0.013	1.23	0.83-1.81	0.31
MSKCC group	1.94	1.64-2.29	<0.001	1.82	1.50-2.20	*<0.001*
ECOG-PS	1.44	1.26-1.64	<0.001	1.40	1.19-1.66	*<0.001*
Time from diagnosis of primary disease (<1 y - 1-5y - >5 y)	0.72	0.64-0.81	<0.001	1.00	0.83-1.21	0.97
Number of bone metastases (single- vs multiple sites)	1.15	0.92-1.43	0.21
Number of other sites of metastasis	1.17	1.04-1.32	0.011	1.06	0.78-1.44	0.70
Other sites of metastasis
Local recurrence	1.05	0.76-1.46	0.78
Lung	1.19	0.96-1.48	0.012	1.41	1.09-1.84	*0.009*
Liver	1.43	1.11-1.84	0.005	1.2	0.87-1.66	0.26
Lymph-nodes	1.30	1.06-1.59	0.014	1.30	1.02-1.67	*0.03*
Adrenals	0.77	0.43-1.37	0.374
Brain	0.91	0.62-1.35	0.65
Other sites	0.60	0.37-0.97	0.04	0.59	0.32-1.09	0.09

HR and significance levels of significant variables are given as computed after removal of non-significant covariates. *UVA: Univariate analysis. **MVA: Multivariate analysis.
cc = clear cell; ECOG-PS = Eastern Cooperative Oncology Group Performance Status; F = female; bold p value represents independent prognostic factor for OS.
M = male; MSKCC = Memorial Sloan Kettering Cancer Center.

ISSN: 1756-9966